|
Development of the different groups at baseline (No work absentism, less than 5 days,...) one year after start of treatment with glatiramer acetate using the same categories (No work absentism, less than 5 days,...). |
||||||||||||
| Baseline |
No work absentism |
≤ 5 days absent |
6–10 days absent |
11–20 days absent |
> 20 days absent |
Not in employment |
||||||
|
|
||||||||||||
| After 12 Months |
N |
% |
N |
% |
N |
% |
N |
% |
N |
% |
N |
% |
|
|
||||||||||||
| No work absentism |
59 |
21.3% |
15 |
5.4% |
20 |
7.2% |
23 |
8.3% |
22 |
7.9% |
9 |
3.3% |
| ≤ 5 days absent |
6 |
2.2% |
8 |
2.9% |
8 |
2.9% |
1 |
0.4% |
4 |
1.4% |
0 |
0% |
| 6–10 days absent |
4 |
1.4% |
1 |
0.4% |
3 |
1.1% |
2 |
0.7% |
4 |
1.4% |
0 |
0% |
| 11–20 days absent |
2 |
0.7% |
2 |
0.7% |
1 |
0.4% |
2 |
0.7% |
1 |
0.4% |
0 |
0% |
| > 20 days absent |
0 |
0% |
0 |
0% |
3 |
1.1% |
1 |
0.4% |
13 |
4.7% |
1 |
0.4% |
| Not in employment |
3 |
1.1% |
0 |
0% |
2 |
0.7% |
1 |
0.4% |
4 |
1.4% |
52 |
18.8% |
Ziemssen et al. Health and Quality of Life Outcomes 2008 6:67 doi:10.1186/1477-7525-6-67 |
||||||||||||